|

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

RECRUITINGN/ASponsored by Third Affiliated Hospital, Sun Yat-Sen University
Actively Recruiting
PhaseN/A
SponsorThird Affiliated Hospital, Sun Yat-Sen University
Started2019-02-21
Est. completion2024-12-31
Eligibility
Age12 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03920618

Summary

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

Eligibility

Age: 12 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Positive hepatitis b surface antigen or hepatitis b virus DNA \> 0.5 year;
2. Age from 12 to 65 years old;
3. Serum total bilirubin level \> 10 times upper limit of normal;
4. Prothrombin time activity \< 40% or prothrombin time international ratio \> 1.5；
5. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

Exclusion Criteria:

1. Other active liver diseases;
2. Hepatocellular carcinoma or other malignancy;
3. Pregnancy or lactation;
4. Human immunodeficiency virus infection or congenital immune deficiency diseases;
5. Severe diabetes, autoimmune diseases;
6. Other important organ dysfunctions;
7. Using glucocorticoid;
8. Patients can not follow-up;
9. Investigator considering inappropriate.

Conditions3

Acute on Chronic Liver FailureHepatitis BLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.